Impact of transcript ratio reduction after chemotherapy by Cox regression analysis
. | 2-3 wk, first induction . | . | 4-8 wk, second induction . | . | 3-4 mo, consolidation . | . | |||
|---|---|---|---|---|---|---|---|---|---|
. | No. . | P . | No. . | P . | No. . | P . | |||
| OS | |||||||||
| AML1-ETO | 64 | .582 | 60 | .610 | 59 | .746 | |||
| CBFB-MYH11 | 64 | .485 | 57 | .465 | 65 | .934 | |||
| PML-RARA | 39 | .389 | 58 | .412 | 36 | .923 | |||
| EFS | |||||||||
| AML1-ETO | 52 | .220 | 74 | .150 | 64 | .038 | |||
| CBFB-MYH11 | 60 | .057 | 83 | .627 | 64 | .155 | |||
| PML-RARA | 39 | .260 | 74 | .201 | 60 | .257 | |||
. | 2-3 wk, first induction . | . | 4-8 wk, second induction . | . | 3-4 mo, consolidation . | . | |||
|---|---|---|---|---|---|---|---|---|---|
. | No. . | P . | No. . | P . | No. . | P . | |||
| OS | |||||||||
| AML1-ETO | 64 | .582 | 60 | .610 | 59 | .746 | |||
| CBFB-MYH11 | 64 | .485 | 57 | .465 | 65 | .934 | |||
| PML-RARA | 39 | .389 | 58 | .412 | 36 | .923 | |||
| EFS | |||||||||
| AML1-ETO | 52 | .220 | 74 | .150 | 64 | .038 | |||
| CBFB-MYH11 | 60 | .057 | 83 | .627 | 64 | .155 | |||
| PML-RARA | 39 | .260 | 74 | .201 | 60 | .257 | |||